Ray Dalio
BBIO icon

Ray Dalio’s BridgeBio Pharma BBIO Stock Holding History

Ray Dalio’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3M Buy
259,459
+216,287
+501% +$15.7M 0.09% 165
2025
Q4 		$3.3M Buy
+43,172
New +$2.83M 0.01% 647

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ray Dalio's BBIO Position: Q1 2026 in Review

Ray Dalio increased its BridgeBio Pharma (BBIO) stake by 501% in Q1 2026, buying an estimated $15.7M and bringing the position to 259,459 shares worth $19.3M. The position accounts for 0.09% of the portfolio, ranked #165.

Ray Dalio first reported a position in BBIO in Q4 2025 and has held it in 2 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Ray Dalio held 259,459 shares of BridgeBio Pharma worth $19.3M as of Q1 2026.
  • Ray Dalio bought 216,287 BridgeBio Pharma shares in Q1 2026, an estimated $15.7M.
  • BridgeBio Pharma made up 0.09% of Ray Dalio's portfolio in Q1 2026, its #165 holding.
  • Ray Dalio first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 2 quarters since.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.